Monitoring Pregnancy Is Key After Wilms’ Treatment

Publication
Article
OncologyONCOLOGY Vol 16 No 11
Volume 16
Issue 11

Women who received radiation therapy for Wilms’ Tumor are at increased risk of complications during pregnancy and, therefore, should be carefully assessed and monitored by their obstetricians. These conclusions were part of a National Wilms’

Women who received radiation therapy for Wilms’ Tumor are at increased risk of complications during pregnancy and, therefore, should be carefully assessed and monitored by their obstetricians. These conclusions were part of a National Wilms’ Tumor Study Group (NWTSG) report published in the Journal of Clinical Oncology (20:2506-2513, 2002). Daniel M. Green, MD, department of pediatrics, Roswell Park Cancer Institute, was the lead author.

"This is the first study to evaluate the risk of increased complicationsof pregnancy due to prior Wilms’ tumor treatment," said Dr. Green."We found that female survivors of Wilms’ tumor who were treated withradiation are at increased risk for early or threatened labor and that theirchildren are more likely to be premature and may be at increased risk of certaincongenital defects. These increased complications were not seen in the partnersof male survivors of Wilms’ tumor who received the same treatment."

Complications and Congenital Malformations

The study was limited to pregnancies of patients or partners of patients whoreceived either no abdominal irradiation or only flank irradiation as part oftheir initial course of treatment. The NWTSG reviewed reports of 427 pregnancieswith a duration of 20 weeks or more, including 409 liveborn singletons. The mostcommon complications identified during pregnancy included malposition of thefetus and early or threatened labor. Offspring of the irradiated women were morelikely to have a low birthweight and be premature (less than 36 weeks’gestation). An increased percentage had one or more congenital malformationssuch as cleft lip and palate, undescended testes, or clubfoot.

"We found that the identified complications were more frequent amongwomen who received a higher radiation therapy dose," said Dr. Green."Additional research is needed to validate these observations and determineif survivors who received lower flank radiation therapy are less likely to havethese complications with a pregnancy. Survivors and their physicians must beaware of these issues when guiding a pregnancy to term."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content